SCHEMBL20028717

SCHEMBL20028717

Cn1cc(C(=O)NC(Cc2ccccc2)C(O)C(N)=O)c(-c2cccc(F)c2)n1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DCAF1 Q9Y4B6 2/20 0.50
▸ PYGL P06737 2/20 0.45
▸ CTSV O60911 1/20 0.41
▸ CTSL P07711 1/20 0.41
▸ CTSS P25774 1/20 0.41
▸ CTSK P43235 1/20 0.41
▸ F2 P00734 2/20 0.41
▸ F10 P00742 2/20 0.41
▸ PRSS1 P07477 2/20 0.41
▸ PRSS2 P07478 2/20 0.41
▸ PRSS3 P35030 2/20 0.41
▸ PSMB5 P28074 2/20 0.39
▸ HPGDS O60760 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ TACR3 P29371 2/20 0.39
▸ KLKB1 P03952 1/20 0.39
▸ KLK1 P06870 1/20 0.39
▸ CARM1 Q86X55 1/20 0.39
▸ CNR1 P21554 1/20 0.38
▸ CNR2 P34972 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22886627 0.91 PYGL (0.48) DCAF1PYGLCTSVCTSLCTSS
SCHEMBL20027478 0.90 PYGL (0.42) DCAF1PYGLPSMB5HPGDSTACR3
SCHEMBL22897214 0.90 DCAF1 (0.51) DCAF1PYGLCTSVCTSLCTSS
SCHEMBL20027914 0.89 DCAF1 (0.48) DCAF1PYGLKMT2AALDH1A1
SCHEMBL22885968 0.87 DCAF1 (0.49) DCAF1PYGLCTSVCTSLCTSS
SCHEMBL22885969 0.86 DCAF1 (0.48) DCAF1PYGLCTSVCTSLCTSS
SCHEMBL20027495 0.86 DCAF1 (0.53) DCAF1CTSVCTSLCTSSCTSK
SCHEMBL21854327 0.86 DCAF1 (0.53) DCAF1CTSVCTSLCTSSCTSK
Hydrochloric Acid SCHEMBL30133652 0.85 DCAF1 (0.52) DCAF1CTSVCTSLCTSSCTSK
SCHEMBL20027718 0.84 DCAF1 (0.51) DCAF1PYGLCTSVCTSLCTSS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11339130-B1 Calpain modulators and therapeutic uses thereof BLADE THERAPEUTICS, INC. (US) 2022-05-24 — — US disclosed
US-10934261-B2 Calpain modulators and therapeutic uses thereof BLADE THERAPEUTICS, INC. (US) 2021-03-02 — — US disclosed
US-10894776-B2 — — 2021-01-19 — — US disclosed
WO-2018064119-A1 CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF BLADE THERAPEUTICS, INC. (US) 2018-04-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10934261-B2 Calpain modulators and therapeutic uses thereof CAPNS1, CAPN9, CAPN1 DCAF1 3091/4885PYGL 925/4885CTSV 314/4885
US-10894776-B2 — CAPNS1, CAPN9, CAPN2 DCAF1 3598/4885PYGL 668/4885CTSV 359/4885
US-11339130-B1 Calpain modulators and therapeutic uses thereof CAPNS1, CAPN9, CAPN1 DCAF1 3091/4885PYGL 925/4885CTSV 314/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback